317 related articles for article (PubMed ID: 27825577)
1. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers.
Juge PA; Truchetet ME; Pillebout E; Ottaviani S; Vigneau C; Loustau C; Cornec D; Pascart T; Snanoudj R; Bailly F; Cornec-Le Gall E; Schaeverbeke T; Saraux A; Dieudé P; Flipo RM; Richette P; Lioté F; Bardin T; Chalès G; Ea HK
Joint Bone Spine; 2017 Oct; 84(5):595-598. PubMed ID: 27825577
[TBL] [Abstract][Full Text] [Related]
2. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
Mitri G; Wittbrodt ET; Turpin RS; Tidwell BA; Schulman KL
J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
[TBL] [Abstract][Full Text] [Related]
3. A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3.
Novella-Navarro M; Cabrera-Alarcon JL; Diaz-Torne C; Aramburu-Muñoz F; Janta I; Ortega de la O MC; Prada-Ojeda A; Sala-Icardo L; Urruticoechea-Arana A; García de la Peña Lefebvre P; Calvo-Aranda E
Rheumatol Int; 2020 Jul; 40(7):1081-1087. PubMed ID: 31982955
[TBL] [Abstract][Full Text] [Related]
4. Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study.
Shen M; Zhang J; Qian K; Li C; Xu W; Gu B; Wang X; Ren Q; Yang L; Yuan H; Su D; Chen X
Clin Rheumatol; 2018 Nov; 37(11):3107-3113. PubMed ID: 30196323
[TBL] [Abstract][Full Text] [Related]
5. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
[TBL] [Abstract][Full Text] [Related]
6. Febuxostat dose requirement according to renal function in patients who achieve target serum urate levels: A retrospective cohort study.
Kim YE; Ahn SM; Oh JS; Kim YG; Lee CK; Yoo B; Hong S
Joint Bone Spine; 2024 Mar; 91(2):105668. PubMed ID: 38036062
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.
Saag KG; Becker MA; Whelton A; Hunt B; Castillo M; Kisfalvi K; Gunawardhana L
Arthritis Rheumatol; 2019 Jan; 71(1):143-153. PubMed ID: 30073793
[TBL] [Abstract][Full Text] [Related]
8. Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis.
Kim SH; Lee SY; Kim JM; Son CN
Korean J Intern Med; 2020 Jul; 35(4):998-1003. PubMed ID: 30959584
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study.
Loustau C; Rosine N; Forien M; Ottaviani S; Juge PA; Lioté F; Bardin T; Richette P; Dieudé P; Richez C; Bannwarth B; Schaeverbeke T; Ea HK; Truchetet ME
Joint Bone Spine; 2018 Dec; 85(6):755-760. PubMed ID: 29654950
[TBL] [Abstract][Full Text] [Related]
10. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
Hu AM; Brown JN
Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037
[TBL] [Abstract][Full Text] [Related]
11. Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment.
Saag KG; Whelton A; Becker MA; MacDonald P; Hunt B; Gunawardhana L
Arthritis Rheumatol; 2016 Aug; 68(8):2035-43. PubMed ID: 26894653
[TBL] [Abstract][Full Text] [Related]
12. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
Lee JW; Lee KH
Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
Singh JA; Akhras KS; Shiozawa A
Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
[TBL] [Abstract][Full Text] [Related]
14. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
[TBL] [Abstract][Full Text] [Related]
15. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
[TBL] [Abstract][Full Text] [Related]
16. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
Sircar D; Chatterjee S; Waikhom R; Golay V; Raychaudhury A; Chatterjee S; Pandey R
Am J Kidney Dis; 2015 Dec; 66(6):945-50. PubMed ID: 26233732
[TBL] [Abstract][Full Text] [Related]
18. Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD.
Sarvepalli PS; Fatima M; Quadri AK; Taher AR; Habeeb A; Amreen F; Parveen BN; Rajaram KG
Saudi J Kidney Dis Transpl; 2018; 29(5):1050-1056. PubMed ID: 30381500
[TBL] [Abstract][Full Text] [Related]
19. A formula predicting the effective dose of febuxostat in chronic kidney disease patients with asymptomatic hyperuricemia based on a retrospective study and a validation cohort
.
Aoun M; Salloum R; Dfouni A; Sleilaty G; Chelala D
Clin Nephrol; 2020 Aug; 94(2):61-69. PubMed ID: 32589132
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.
Gunawardhana L; Becker MA; Whelton A; Hunt B; Castillo M; Saag K
Arthritis Res Ther; 2018 May; 20(1):99. PubMed ID: 29848361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
